Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, solution - excipient ingredients: sodium; octanoate - hypoproteinaemia in the acutely ill patient - albapure 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock - albapure 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma. severe burns - extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. iso-oncotic albumin solution is the preferred replacement material. if the patient's serum albumin level is not maintained, concentrated albumin (20%) may be indicated. if exchange occurs less frequently than once a week, less concentrated colloids may be appropriate.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, solution - excipient ingredients: sodium; octanoate - 1. hypoproteinaemia in the acutely ill patient. albapure 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. 2. shock. albapure 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. 3. burns. extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. initially (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albapure 20 are required to maintain adequate plasma volume and colloid osmotic pressure. 4. adult respiratory distress syndrome. the clinical syndrome is characterised by inadequate oxygenation secondary to pulmonary interstitial oedema, complicating shock and postoperative states resulting in a decreased central venous pressure, decreased plasma albumin concentration, rising blood pressure, reduced cardiac output, lowered pulse rate and a falling renal output. the acute condition can be controlled by diuretics and albapure 20 in amounts sufficient to maintain vital signs. in patients who have undergone abdominal surgery, the intravenous administration of albumin solution (20%) immediately after the operation has been shown to improve lung compliance and gaseous exchange. 5. haemodialysis albapure 20 may be used to assist with the rapid removal of excess extravascular fluid and to maintain perfusion pressure. 6. therapeutic plasma exchange therapeutic plasma exchange is a procedure in which approximately one plasma volume is exchanged with a colloid replacement solution. the choice of replacement fluid and its concentration are determined by the particular clinical situation and the frequency of the procedure.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.